Jihua Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jihua Liu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Annlia Paganini-Hill
Beckman Laser Institute and Medical Clinic, University of California-Irvine School of Medicine, Irvine, CA, USA
1 shared publication - David H. Cribbs
Institute for Memory Impairments and Neurological Disorders, University of California , Irvine, Irvine, CA, 92697
1 shared publication - Donghy Lee
Department of Neurology, University of California , Irvine, Orange, CA, 92868
1 shared publication - Jiamin Yan
Department of Neurology, University of California , Irvine, Orange, CA, 92868
1 shared publication - Kalpna Gupta
Hematology/Oncology, Department of Medicine, University of California, Irvine, CA 92697, USA
1 shared publication - Mark Fisher
Department of Neurology, University of California, Irvine, CA 92697, USA
1 shared publication
Latest Publications
- Open Access
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1) , yoag015
Cerebral microhemorrhages in a mouse model of sickle cell disease
Objectives: Stroke in sickle cell disease (SCD) is often attributed to large vessel involvement in the disorder, whereas the contribution of cerebral microvascular disease has been less explored. In this study, we investigated the formation of cerebral microvascular lesions and the involvement of mast cells in a humanized SCD mouse model. Methods: We studied hemorrhagic microvascular disease in a well-characterized mouse model of humanized transgenic sickle (HbSS-BERK) expressing >99% human sickle hemoglobin (HbS) and a control (HbAA-BERK) mouse model expressing normal human hemoglobin A (HbA). Mouse brains were analyzed by Prussian blue staining to detect cerebral microhemorrhage (CMH) formation. Mast cell identification was performed by toluidine blue staining. Results: SCD brain sections exhibited approximately 86% more CMH than controls (mean ± SE of 1.17 ± 0.22 vs. 0.63 ± 0.13 number/cm2, P = .02). Mast cells were positively correlated with CMH number in SCD mice (Spearman r = 0.42, P < .05), but not in control mice. Conclusion: SCD mice demonstrated significantly increased CMH load compared with control mice, and SCD microhemorrhages were associated with the number of mast cells. These findings highlight the significance of cerebral microvascular disease in SCD and imply that cerebral mast cells may be a novel therapeutic target in SCD.
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1) , yoag015
Open AccessCerebral microhemorrhages in a mouse model of sickle cell disease
Objectives: Stroke in sickle cell disease (SCD) is often attributed to large vessel involvement in the disorder, whereas the contribution of cerebral microvascular disease has been less explored. In this study, we investigated the formation of cerebral microvascular lesions and the involvement of mast cells in a humanized SCD mouse model. Methods: We studied hemorrhagic microvascular disease in a well-characterized mouse model of humanized transgenic sickle (HbSS-BERK) expressing >99% human sickle hemoglobin (HbS) and a control (HbAA-BERK) mouse model expressing normal human hemoglobin A (HbA). Mouse brains were analyzed by Prussian blue staining to detect cerebral microhemorrhage (CMH) formation. Mast cell identification was performed by toluidine blue staining. Results: SCD brain sections exhibited approximately 86% more CMH than controls (mean ± SE of 1.17 ± 0.22 vs. 0.63 ± 0.13 number/cm2, P = .02). Mast cells were positively correlated with CMH number in SCD mice (Spearman r = 0.42, P < .05), but not in control mice. Conclusion: SCD mice demonstrated significantly increased CMH load compared with control mice, and SCD microhemorrhages were associated with the number of mast cells. These findings highlight the significance of cerebral microvascular disease in SCD and imply that cerebral mast cells may be a novel therapeutic target in SCD.